TW200728299A - New pyrazine derivatives - Google Patents

New pyrazine derivatives

Info

Publication number: TW200728299A
Authority: TW; Taiwan
Prior art keywords: antagonist; diseases; pyrazine derivatives; kinase inhibitor; receptor
Prior art date: 2005-07-29

Application number

TW095127615A

Other languages

English (en)

Inventor

Juan Bernat Vidal

Trias Cristina Esteve

Pueyo Lidia Soca

Paul Robert Eastwood

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2006-07-28

Publication date

2007-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35945119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200728299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-07-28 Application filed by Almirall Lab filed Critical Almirall Lab

2007-08-01 Publication of TW200728299A publication Critical patent/TW200728299A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095127615A 2005-07-29 2006-07-28 New pyrazine derivatives TW200728299A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200501876A ES2270715B1 (es)	2005-07-29	2005-07-29	Nuevos derivados de pirazina.

Publications (1)

Publication Number	Publication Date
TW200728299A true TW200728299A (en)	2007-08-01

Family

ID=35945119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095127615A TW200728299A (en)	2005-07-29	2006-07-28	New pyrazine derivatives

Country Status (22)

Country	Link
US (2)	US7790728B2 (zh)
EP (1)	EP1922313A1 (zh)
JP (1)	JP2009502837A (zh)
KR (1)	KR20080040681A (zh)
CN (1)	CN101268064A (zh)
AR (1)	AR056008A1 (zh)
AU (1)	AU2006278875A1 (zh)
CA (1)	CA2616428A1 (zh)
EC (1)	ECSP088113A (zh)
ES (1)	ES2270715B1 (zh)
IL (1)	IL188725A0 (zh)
MX (1)	MX2008001035A (zh)
NO (1)	NO20080451L (zh)
NZ (1)	NZ565150A (zh)
PE (1)	PE20070407A1 (zh)
RU (1)	RU2417994C2 (zh)
SG (1)	SG162805A1 (zh)
TW (1)	TW200728299A (zh)
UA (1)	UA93883C2 (zh)
UY (1)	UY29672A1 (zh)
WO (1)	WO2007017096A1 (zh)
ZA (1)	ZA200800353B (zh)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006208045B2 (en)	2005-01-25	2012-08-30	Synta Pharmaceuticals Corp.	Compounds for inflammation and immune-related uses
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
RU2478635C2 (ru) *	2006-10-19	2013-04-10	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
ES2303776B1 (es) *	2006-12-29	2009-08-07	Laboratorios Almirall S.A.	Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2716223A1 (en) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
BRPI0909157A2 (pt)	2008-03-26	2015-11-24	Advinus Therapeutics Private Ltd	compostos heterocíclicos como antagonistas de receptores de adenosina
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
HRP20140265T1 (hr)	2009-02-06	2014-04-25	Nippon Shinyaku Co., Ltd.	Derivat aminopirazina i odgovarajuä†i lijek
BRPI1009398A2 (pt)	2009-03-13	2016-03-08	Advinus Therapeutics Private Ltd	compostos de pirimidina fundida substituída
US8796290B2 (en)	2009-11-09	2014-08-05	Advinus Therapeutics Limited	Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338890A1 (en)	2009-12-22	2011-06-29	Bayer CropScience AG	4,7-Diazaindole derivatives and their use as fungicides
SG183146A1 (en) *	2010-02-05	2012-09-27	Heptares Therapeutics Ltd	1,2,4-triazine-4-amine derivatives
CN101817823B (zh) *	2010-03-31	2012-09-12	上海毕得医药科技有限公司	4，7-二氮杂吲哚及其5位取代物的制备方法
PH12013500084A1 (en)	2010-07-14	2015-09-11	Novartis Ag	Ip receptor agonist heterocyclic compounds
CN103261200B (zh)	2010-09-13	2016-03-30	阿迪维纳斯疗法有限公司	作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
TWI659030B (zh) *	2011-10-26	2019-05-11	諾華公司	Ｉｐ受體促效劑雜環化合物
UY34572A (es) *	2012-01-13	2013-09-02	Novartis Ag	Compuestos heterocíclicos agonistas del receptor ip
WO2013105061A1 (en) *	2012-01-13	2013-07-18	Novartis Ag	Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802581A1 (en) *	2012-01-13	2014-11-19	Novartis AG	7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2561353T3 (es) *	2012-01-13	2016-02-25	Novartis Ag	Sales de un agonista del receptor IP
US9115129B2 (en)	2012-01-13	2015-08-25	Novartis Ag	Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
WO2013105063A1 (en) *	2012-01-13	2013-07-18	Novartis Ag	Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AU2013268400B2 (en)	2012-05-30	2017-07-13	Nippon Shinyaku Co., Ltd.	Aromatic heterocyclic derivative and pharmaceutical
CN107652289B (zh)	2012-06-13	2020-07-21	因塞特控股公司	作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014087208A2 (en) *	2012-12-06	2014-06-12	Enaltec Labs Pvt. Ltd.	A process of preparing alcaftadine
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
CN105189500A (zh)	2013-02-13	2015-12-23	诺华股份有限公司	Ip受体激动剂杂环化合物
KR102269032B1 (ko)	2013-04-19	2021-06-24	인사이트 홀딩스 코포레이션	Fgfr 저해제로서 이환식 헤테로사이클
CN103364500B (zh) *	2013-06-29	2019-01-22	北京万全德众医药生物技术有限公司	一种用液相色谱法分离测定比拉斯汀原料及其制剂的方法
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MX381180B (es) *	2014-11-18	2025-03-12	Merck Sharp & Dohme	Compuestos aminopirazina con propiedades antagonistas a2a.
CN104402833B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	吡嗪类化合物及其组合物及用途
CN104447583B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) *	2014-12-10	2016-08-24	广东东阳光药业有限公司	吡嗪衍生物及其用途
US10336702B2 (en)	2014-12-23	2019-07-02	Bergenbio Asa	Pharmaceutically active compounds
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es)	2015-02-20	2017-10-20	Incyte Corp	Heterociclos biciclicos como inhibidores de fgfr
ES2580702B1 (es) *	2015-02-25	2017-06-08	Palobiofarma, S.L.	Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7013213B2 (ja) *	2017-05-26	2022-01-31	日本化薬株式会社	ピラジン化合物
EP3654978A4 (en) *	2017-07-18	2021-03-31	Nuvation Bio Inc.	HETEROCYCLIC COMPOUNDS USED AS ADENOSINE ANTAGONISTS
JP2020527593A (ja)	2017-07-18	2020-09-10	ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎＢｉｏＩｎｃ．	１，８−ナフチリジノン化合物およびその使用
JP2021522327A (ja)	2018-04-20	2021-08-30	バージニア・テック・インテレクチュアル・プロパティーズ・インコーポレイテッドＶｉｒｇｉｎｉａＴｅｃｈＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｉｅｓ，Ｉｎｃ．	ミトコンドリア脱共役剤として有用なオキサジアゾロピラジンおよびオキサジアゾロピリジン
SG11202010636VA (en)	2018-05-04	2020-11-27	Incyte Corp	Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt)	2018-05-04	2021-02-02	Incyte Corporation	sais de um inibidor de fgfr
CN109020881B (zh) *	2018-06-28	2020-04-28	新发药业有限公司	一种阿帕替尼的制备方法
CN115181092B (zh) *	2018-08-17	2024-05-03	迪哲(江苏)医药股份有限公司	吡嗪化合物和其用途
AU2019367187A1 (en) *	2018-10-24	2021-03-25	Leadxpro Ag	Functionalized aminotriazines
CN111377873B (zh) *	2018-12-28	2023-03-28	四川科伦博泰生物医药股份有限公司	氨基嘧啶化合物及其制备方法和用途
CN111377906B (zh) *	2018-12-28	2022-09-02	四川科伦博泰生物医药股份有限公司	取代的吡嗪化合物及其制备方法和用途
KR20210110288A (ko) *	2018-12-28	2021-09-07	쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드	치환된 아릴 화합물, 및 이의 제조 방법 및 이의 용도
AU2020207952A1 (en) *	2019-01-18	2021-08-26	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
MX2021008650A (es)	2019-01-18	2021-11-03	Nuvation Bio Inc	Compuestos heterociclicos como antagonistas de adenosina.
US11254670B2 (en)	2019-01-18	2022-02-22	Nuvation Bio Inc.	1,8-naphthyridinone compounds and uses thereof
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
CN110407677B (zh) *	2019-06-17	2022-10-11	南京先进生物材料与过程装备研究院有限公司	二苯乙二酮类化合物的制备方法及应用
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN112608316B (zh) *	2019-07-30	2022-10-21	厦门宝太生物科技股份有限公司	一种吡唑并三嗪类腺苷受体拮抗剂
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
JP7720840B2 (ja)	2019-12-04	2025-08-08	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021146631A1 (en) *	2020-01-17	2021-07-22	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
WO2021146629A1 (en) *	2020-01-17	2021-07-22	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN116903634B (zh) *	2023-07-17	2025-07-29	上海美迪西生物医药股份有限公司	一种6-苯基噻吩并[2,3-b]吡嗪的制备方法
WO2025036840A1 (en) *	2023-08-11	2025-02-20	Almirall, S.A.	Pyridine or pyrazine derivatives as collagen vii (c7) inducers and their use in therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9309573D0 (en)	1993-05-10	1993-06-23	Merck Sharp & Dohme	Therapeutic agents
US5686470A (en)	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation
EP0888335A4 (en)	1996-03-13	2002-01-02	Smithkline Beecham Corp	NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
DE19632549A1 (de) *	1996-08-13	1998-02-19	Merck Patent Gmbh	Arylalkanoylpyridazine
WO1998024782A2 (en)	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidine compounds and their use
AU755421B2 (en)	1997-12-19	2002-12-12	Amgen, Inc.	Substituted pyridine and pyridazine compounds and their pharmaceutical use
KR100581199B1 (ko)	1998-06-19	2006-05-17	카이론 코포레이션	글리코겐 신타제 키나제 3의 억제제
US6545002B1 (en)	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6841549B1 (en)	1999-07-02	2005-01-11	Eisai Co., Ltd.	Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
NZ517546A (en)	1999-08-31	2003-10-31	Univ Vanderbilt	Selective antagonists of A2B adenosine receptors
EP1255550A2 (en)	2000-02-17	2002-11-13	Cv Therapeutics, Inc.	Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
DE60110391T2 (de)	2000-02-25	2006-01-26	F. Hoffmann-La Roche Ag	Adenosin-rezeptor modulatoren
NZ521633A (en)	2000-04-26	2005-01-28	Eisai Co Ltd	Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement
DE60140126D1 (de)	2000-08-11	2009-11-19	Eisai R&D Man Co Ltd	2-aminopyridin-verbindungen und ihre verwendung als medikamente
WO2002020495A2 (en)	2000-09-06	2002-03-14	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
ES2242771T5 (es)	2000-09-15	2011-10-14	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol útiles como inhibidores de proteína quinasas.
KR100793263B1 (ko)	2000-09-19	2008-01-10	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	ＧＳＫ-3β 단백질의 특성확인 및 그것의 이용 방법
GB0028383D0 (en)	2000-11-21	2001-01-03	Novartis Ag	Organic compounds
KR100897219B1 (ko)	2001-06-29	2009-05-14	씨브이 쎄러퓨틱스, 인코포레이티드	Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
TWI330183B (zh)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
US6977300B2 (en)	2001-11-09	2005-12-20	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US7125993B2 (en)	2001-11-09	2006-10-24	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
HU229504B1 (hu)	2001-11-09	2014-01-28	Gilead Sciences	A2B-adenozinreceptor-antagonisták
US20050043315A1 (en)	2002-01-02	2005-02-24	Hideo Tsutsumi	Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
KR20040080939A (ko)	2002-02-01	2004-09-20	킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨	8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
WO2003068773A1 (en)	2002-02-12	2003-08-21	Glaxo Group Limited	Pyrazolopyridine derivatives
CA2479744A1 (en)	2002-03-28	2003-10-09	Paul E. Finke	Substituted 2,3-diphenyl pyridines
RS107404A (sr)	2002-06-12	2007-02-05	Biogen Idec Ma Inc.,	Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora
US20040067955A1 (en)	2002-09-06	2004-04-08	Fujisawa Pharmaceutical Co. Ltd.	Pyridazinone compound and pharmaceutical use thereof
BR0315053A (pt)	2002-10-03	2005-08-09	Targegen Inc	Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
SI1611131T1 (sl)	2003-02-27	2011-03-31	Palau Pharma Sa	Pirazolopiridinski derivati
CA2524778C (en)	2003-05-06	2013-01-29	Cv Therapeutics, Inc.	Xanthine derivatives as a2b adenosine receptor antagonists
PT1658291E (pt)	2003-08-25	2013-10-21	Dogwood Pharmaceuticals Inc	8-heteroarilxantinas substituídas
ES2229928B1 (es)	2003-10-02	2006-07-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en)	2003-10-03	2003-11-05	Chang Lisa C W	Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) *	2003-10-27	2005-05-06	Astellas Pharma Inc.	Pyrazine derivatives and pharmaceutical use thereof
CN1890241A (zh)	2003-10-31	2007-01-03	Cv医药有限公司	A2b腺苷受体拮抗剂
GB0401336D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
ES2303776B1 (es)	2006-12-29	2009-08-07	Laboratorios Almirall S.A.	Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

2005
- 2005-07-29 ES ES200501876A patent/ES2270715B1/es not_active Expired - Fee Related
2006
- 2006-07-13 UY UY29672A patent/UY29672A1/es unknown
- 2006-07-25 EP EP06762807A patent/EP1922313A1/en not_active Withdrawn
- 2006-07-25 RU RU2008107264/04A patent/RU2417994C2/ru not_active IP Right Cessation
- 2006-07-25 SG SG201004274-5A patent/SG162805A1/en unknown
- 2006-07-25 PE PE2006000899A patent/PE20070407A1/es not_active Application Discontinuation
- 2006-07-25 AU AU2006278875A patent/AU2006278875A1/en not_active Abandoned
- 2006-07-25 UA UAA200802498A patent/UA93883C2/ru unknown
- 2006-07-25 CN CNA2006800340045A patent/CN101268064A/zh active Pending
- 2006-07-25 KR KR1020087002157A patent/KR20080040681A/ko not_active Withdrawn
- 2006-07-25 NZ NZ565150A patent/NZ565150A/en unknown
- 2006-07-25 WO PCT/EP2006/007318 patent/WO2007017096A1/en not_active Ceased
- 2006-07-25 CA CA002616428A patent/CA2616428A1/en not_active Abandoned
- 2006-07-25 MX MX2008001035A patent/MX2008001035A/es not_active Application Discontinuation
- 2006-07-25 US US11/997,048 patent/US7790728B2/en not_active Expired - Fee Related
- 2006-07-25 JP JP2008523220A patent/JP2009502837A/ja active Pending
- 2006-07-28 TW TW095127615A patent/TW200728299A/zh unknown
- 2006-07-28 AR ARP060103279A patent/AR056008A1/es not_active Application Discontinuation
2008
- 2008-01-10 IL IL188725A patent/IL188725A0/en unknown
- 2008-01-11 ZA ZA200800353A patent/ZA200800353B/xx unknown
- 2008-01-17 EC EC2008008113A patent/ECSP088113A/es unknown
- 2008-01-24 NO NO20080451A patent/NO20080451L/no not_active Application Discontinuation
2010
- 2010-06-04 US US12/794,059 patent/US20100273757A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7790728B2 (en)	2010-09-07
RU2417994C2 (ru)	2011-05-10
ECSP088113A (es)	2008-02-20
AR056008A1 (es)	2007-09-12
UA93883C2 (ru)	2011-03-25
EP1922313A1 (en)	2008-05-21
RU2008107264A (ru)	2009-09-10
AU2006278875A1 (en)	2007-02-15
CA2616428A1 (en)	2007-02-15
NO20080451L (no)	2008-02-11
CN101268064A (zh)	2008-09-17
NZ565150A (en)	2011-02-25
ZA200800353B (en)	2008-12-31
IL188725A0 (en)	2008-08-07
MX2008001035A (es)	2008-03-14
UY29672A1 (es)	2007-01-31
US20100273757A1 (en)	2010-10-28
ES2270715B1 (es)	2008-04-01
WO2007017096A1 (en)	2007-02-15
US20090042891A1 (en)	2009-02-12
KR20080040681A (ko)	2008-05-08
JP2009502837A (ja)	2009-01-29
SG162805A1 (en)	2010-07-29
PE20070407A1 (es)	2007-05-12
ES2270715A1 (es)	2007-04-01

Publication	Publication Date	Title
TW200728299A (en)	2007-08-01	New pyrazine derivatives
KR102488479B1 (ko)	2023-01-12	인플루엔자 바이러스 감염에 사용하기 위한 인돌
US8470835B2 (en)	2013-06-25	Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
CN101801362B (zh)	2014-01-22	用于治疗病症的方法和组合物
US8389546B2 (en)	2013-03-05	Compounds for modulating TRPV3 function
WO2006067445A3 (en)	2006-09-14	Csf-1r kinase inhibitors
HUE032847T2 (hu)	2017-11-28	Vegyületek és készítmények mint protein kináz inhibitorok
WO2007022380A3 (en)	2007-06-21	Bis-aryl amide compounds and methods of use
MY147442A (en)	2012-12-14	Imidazoquinolines as lipid kinase inhibitors
JP6463680B2 (ja)	2019-02-06	脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
WO2008002245A3 (en)	2008-02-14	Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
UA92181C2 (ru)	2010-10-11	Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
TW200927129A (en)	2009-07-01	Organic compounds
MX2007008614A (es)	2007-09-11	Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
NO20091254L (no)	2009-03-26	Terapeutiske sammensetninger
CN101460508A (zh)	2009-06-17	噻唑基-二氢-喹唑啉
Kelly et al.	2015	α2-adrenoceptor antagonists: synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives
WO2020247298A3 (en)	2021-01-07	1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CN105683202A (zh)	2016-06-15	2-[5-[n-(4-氟苯基)氨基甲酰]嘧啶-2-基巯甲基]-4-(三氟甲氧基)苯基]硼酸
Eswayah et al.	2017	Synthesis and analgesic activity evaluation of some new benzimidazole derivatives
JP2023533616A (ja)	2023-08-03	Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法
WO2008039139A8 (en)	2009-03-19	Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
CN101684098A (zh)	2010-03-31	一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
Wurz et al.	2010	Part 2: Structure–activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
ES3030634T3 (en)	2025-07-01	Substituted pyrrolo [2, 3-d]pyridazin-4-ones and pyrazolo [3, 4-d]pyridazin-4-ones as protein kinase inhibitors